RYTM Rhythm Pharmaceuticals (RYTM) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001649904
Form 144 · 8
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
173
13F, latest reported quarter
Conversions, 180 days
17
Codes C/M, not in net · $4.4M priced
What the filings say about RYTM
Insiders, 180 days
-$32.9M net sold
8 sellers · 36% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$30.5M
8 notices
Rhythm Pharmaceuticals insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, RHYTHM PHARMACEUTICALS, INC. insiders sold a net $32.9M of stock across 225 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-29.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2025.
- The trade is 2.3% of the 282,819 shares held after it.
- 1 other insider sold within 30 days.
- 173 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Meeker David P sold about $655.1K of RYTM under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 173 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2025.
- The trade is 12.2% of the 252,073 shares held after it.
- 1 other insider sold within 30 days.
- 173 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Meeker David P sold about $3.1M of RYTM under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 173 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2025.
- The trade is 3.6% of the 243,375 shares held after it.
- 1 other insider sold within 30 days.
- 173 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Meeker David P sold about $899.6K of RYTM under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 173 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2025.
- The trade is 0.8% of the 241,558 shares held after it.
- 1 other insider sold within 30 days.
- 173 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Meeker David P sold about $190.0K of RYTM under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 173 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Jun 3, 2025.
- The trade is 1.0% of the 239,258 shares held after it.
- 1 other insider sold within 30 days.
- 173 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Meeker David P sold about $241.9K of RYTM under a 10b5-1 plan on Sep 14, 2026; 1 other insider sold within 30 days and 173 funds added in the latest 13F quarter.225 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$32.9M over 180 days
-$28.8M over 90 days
below 92% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
173 funds bought in last quarter
more than 86% of Pharma & Biotech
Revenue
+45.8% year over year
more than 75% of Pharma & Biotech
Margin
-103.6% net margin
below 58% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
19.6% of the float short (float per yahoo 2026-10-27) · 13.5 days to cover · settled 2026-10-15
more than 88% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch RYTM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-16.6%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns RYTM: institutional holders (13F)
13F holdings, latest reported quarter
6,666,837 sh
$740.2M
6,156,902 sh
$683.6M
5,604,483 sh
$622.3M
3,168,853 sh
$351.8M
3,136,895 sh
$348.3M
Congress trades in RYTM
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
RYTM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
David Meeker
Filed 2026-09-14
$5.2M
HUNTER SMITH
Filed 2026-08-31
$6.7M
ALASTAIR GARFIELD
Filed 2026-08-13
$912.9K
Jennifer Kayden Lee
Filed 2026-08-13
$8.9M
JOSEPH J SHULMAN
Filed 2026-08-13
$597.3K
RYTM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Harbor Health Care ETF
$1.7M position · as of 2026-07-31
4.0%
PRIMECAP Odyssey Aggressive Growth Fund
$195.3M position · as of 2026-07-31
2.6%
AlphaCentric Life Sciences and Healthcare Fund
$1.0M position · as of 2026-06-30
2.2%
Federated Hermes Kaufmann Fund II
$2.5M position · as of 2026-06-30
2.2%
Federated Hermes Kaufmann Small Cap Fund
$60.5M position · as of 2026-07-31
2.1%
Federated Hermes Kaufmann Fund
$101.9M position · as of 2026-07-31
2.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
21 registered trials, 5 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
8
Phase 2
2 active
9
Phase 3
2 active
1
Phase 4
0 active
3
Multi-phase
1 active
What changed recently
A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
2026-10-10 · Recruiting → Active Not Recruiting
PHASE1,PHASE2
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · David P. Meeker
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$17.5M
$54.2M
$5.6M
+260%
-6%
2024
$14.7M
$18.7M
$4.6M
+88%
-7%
2023
$7.2M
$19.0M
$2.0M
+55%
-6%
2022
$3.3M
$24.1M
$1.1M
-2%
-10%
2021
$6.5M
-$10.0M
$2.1M
-66%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $32.9M sold by insiders over 180 days, 173 funds added last quarter, $30.5M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
RYTM financials
Revenue growth
+45.8%
XBRL, annual
Net margin
-103.6%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$239.9M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM RYTM
| FY Dec 2025 | $189.8M |
| FY Dec 2024 | $130.1M |
| FY Dec 2023 | $77.4M |
| FY Dec 2022 | $23.6M |
| FY Dec 2021 | $3.2M |
| Jun 2026 | $71.3M |
| Mar 2026 | $60.1M |
| Dec 2025 | $57.3M |
| Sep 2025 | $51.3M |
| Jun 2025 | $48.5M |
| Mar 2025 | $32.7M |
| Dec 2024 | $41.8M |
| Sep 2024 | $33.3M |
At each fiscal year end
Single quarter
Net margin, TTM
-3.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM RYTM
| FY Dec 2025 | -0.1% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.2% |
| FY Dec 2022 | -0.8% |
| FY Dec 2021 | -2.2% |
| Jun 2026 | -69.2% |
| Mar 2026 | -92.6% |
| Dec 2025 | +260.0% |
| Sep 2025 | -103.1% |
| Jun 2025 | -96.1% |
| Mar 2025 | -151.4% |
| Dec 2024 | +518.9% |
| Sep 2024 | -131.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$105.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM RYTM
| FY Dec 2025 | -$115.7M |
| FY Dec 2024 | -$113.9M |
| FY Dec 2023 | -$136.2M |
| FY Dec 2022 | -$173.7M |
| FY Dec 2021 | -$146.4M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
1.03x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity RYTM
| FY Dec 2025 | 0.78x |
| FY Dec 2024 | 5.05x |
| FY Dec 2023 | 0.63x |
| FY Dec 2022 | 0.28x |
| FY Dec 2021 | n/a |
| Jun 2026 | 1.03x |
| Mar 2026 | 0.88x |
| Dec 2025 | 0.78x |
| Sep 2025 | 0.73x |
| Jun 2025 | n/a |
| Mar 2025 | 5.78x |
| Dec 2024 | 5.05x |
| Sep 2024 | 9.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.99x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt RYTM
| FY Dec 2025 | -1.07x |
| FY Dec 2024 | -1.04x |
| FY Dec 2023 | -1.28x |
| FY Dec 2022 | -2.38x |
| FY Dec 2021 | n/a |
| Jun 2026 | -0.99x |
| Mar 2026 | -1.10x |
| Dec 2025 | -1.07x |
| Sep 2025 | -1.00x |
| Jun 2025 | -0.98x |
| Mar 2025 | -1.04x |
| Dec 2024 | -1.04x |
| Sep 2024 | -1.17x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-19.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity RYTM
| FY Dec 2025 | -0.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -19.8% |
| Mar 2026 | -8.9% |
| Dec 2025 | -0.2% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -71.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-2.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets RYTM
| FY Dec 2025 | -0.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -0.1% |
| FY Dec 2022 | -0.1% |
| FY Dec 2021 | -0.0% |
| Jun 2026 | -2.2% |
| Mar 2026 | -1.5% |
| Dec 2025 | -0.0% |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | -20.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital RYTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-72.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed RYTM
| FY Dec 2025 | -59.0% |
| FY Dec 2024 | -95.8% |
| FY Dec 2023 | -59.4% |
| FY Dec 2022 | -57.0% |
| FY Dec 2021 | -74.7% |
| Jun 2026 | -72.0% |
| Mar 2026 | -64.3% |
| Dec 2025 | -59.0% |
| Sep 2025 | -55.7% |
| Jun 2025 | -62.2% |
| Mar 2025 | -72.0% |
| Dec 2024 | -95.8% |
| Sep 2024 | -93.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing RYTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$6.4B
market value at close 2026-10-27 on 2026-08-01 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value RYTM
| FY Dec 2025 | $7.2B |
| FY Dec 2024 | $3.5B |
| FY Dec 2023 | $2.8B |
| FY Dec 2022 | $1.6B |
| FY Dec 2021 | n/a |
| Jun 2026 | $7.6B |
| Mar 2026 | $6.0B |
| Dec 2025 | $7.2B |
| Sep 2025 | $6.8B |
| Jun 2025 | $4.0B |
| Mar 2025 | $3.4B |
| Dec 2024 | $3.5B |
| Sep 2024 | $3.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.7%
TTM free cash flow over market value at close 2026-10-27
FCF yield RYTM
| FY Dec 2025 | -1.6% |
| FY Dec 2024 | -3.3% |
| FY Dec 2023 | -5.0% |
| FY Dec 2022 | -10.6% |
| FY Dec 2021 | -29.2% |
| Jun 2026 | -1.4% |
| Mar 2026 | -2.0% |
| Dec 2025 | -1.6% |
| Sep 2025 | -1.6% |
| Jun 2025 | -2.7% |
| Mar 2025 | -3.4% |
| Dec 2024 | -3.3% |
| Sep 2024 | -3.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing RYTM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $189.8M | $130.1M | $77.4M | $23.6M |
| Operating income | -$192.0M | -$265.5M | -$184.4M | -$179.2M |
| Net income | -$196.5K | -$260.6K | -$184.7K | -$181.1K |
| EPS (diluted) | n/a | n/a | n/a | n/a |
| Operating cash flow | -$115.7M | -$113.9M | -$136.2M | -$173.4M |
| Cash | $54.3M | $89.1M | $60.1M | $127.7M |
| Long-term debt | $100.9M | $108.3M | $106.1M | n/a |
SEC XBRL, fiscal years, as known on 2026-10-29
RYTM Stock Sonar score 6/7 axes
Find similar shapesCompareRYTM ranks highest on institutional and government (86th percentile) and growth (75th), and lowest on insider conviction (5th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
RYTM filings, in plain words
Are Rhythm Pharmaceuticals insiders buying or selling RYTM?
In the 180 days to 2026-10-29, Rhythm Pharmaceuticals insiders were net sellers, a net $32.9M across purchases and sales reported on Form 4, by 8 sellers.
Are there planned insider sales of RYTM?
Yes. 8 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-29, covering $30.5M of stock; the latest, by David Meeker, was filed 2026-09-14.
Read the full summary
In the 180 days to 2026-10-29, Rhythm Pharmaceuticals insiders were net sellers of RYTM, a net $32.9M across purchases and sales reported on Form 4 by 8 sellers. 36% of the 22 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 8 Form 144 notices of intent to sell in the 90 days to 2026-10-29, covering $30.5M of stock. Each figure is counted from SEC and House filings as of 2026-10-29, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
